Primary lymphomas of the skull are extremely rare, as fewer than 20 cases have been reported in the literature. We describe the case of a 51-year-old woman with Huntington chorea who presented with forehead swelling. Imaging studies detected an enhancing mass in the skull with some destruction of the underlying bone. These features were suggestive of osteomyelitis. Surgical excision was performed, and the mass was found to be a primary diffuse large B-cell lymphoma. The patient was administered postoperative chemotherapy, and she was in complete remission at the 1-year follow-up. Figure 3. Histology identifi es the mass as a diffuse large B-cell lymphoma. The tumor cells contain large nuclei, open chromatin, and prominent nucleoli. Volume 90, Number 1 www.entjournal.com ■ E25 PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE SKULL MIMICKING OSTEOMYELITIS
Introduction
Between 10 and 34% of all non-Hodgkin lymphomas arise from extranodal sites. 1 Primary lymphoma of bone accounts for about 5% of all extranodal malignant lymphomas. 2 The skull is a very rare site for a primary extranodal lymphoma. The nature of the clinical signs and symptoms of a malignant lymphoma of the skull depends on the precise location of the mass; patients may present with localized swelling, eyelid swelling, pain, paresthesia and, if there is intra-axial extension, neurologic symptoms. We report a new case of primary lymphoma of the skull-one that mimicked osteomyelitis.
Case report
A 51-year-old black woman presented with painful swelling of the right forehead and upper eyelid of 3 weeks' duration. She denied systemic symptoms-in particular, fever and chills-and any recent upper respiratory infection. Her medical history was signifi cant for Huntington chorea and uterine fi broids. Her medications included haloperidol for the chorea. Her family history was unremarkable.
On physical examination, the patient was alert and well oriented. She was afebrile and exhibited no focal neurologic defi cits except for choreiform movements of the upper extremities. A diffuse, tender, and nonfl uctuant area of swelling was present over the right side of her forehead. Laboratory studies revealed a normal blood count with an erythrocyte sedimentation rate of 26 mm/ hr and a C-reactive protein level of 1.0 mg/L. Computed tomography (CT) of the head and orbit was suggestive of sinusitis, osteomyelitis of the frontal bone, and epidural abscess (fi gure 1). Magnetic resonance imaging (MRI) of the brain was reported as right frontal sinusitis, right frontal osteomyelitis, cerebritis, and subdural empyema (fi gure 2).
The patient was admitted to the hospital and started on vancomycin and meropenem for presumed osteomyelitis. Then the neurosurgery service was consulted, and a decision was made to perform a bifrontal craniectomy, removal of the frontal subdural mass, and cranialization and exenteration of the frontal sinus. Analysis of the cerebrospinal fl uid revealed a normal cell count and chemistry, and bacterial, fungal, and mycobacterial cultures were negative. Similarly, cultures of the mass and of bone were also negative. However, surgical pathology unexpectedly revealed a diffuse large B-cell lymphoma involving the frontal bone (fi gure 3). Subsequent testing for the presence of human immunodefi ciency virus was negative, and the lactic dehydrogenase level was normal.
Positron-emission tomography (PET) combined with CT (PET/CT) demonstrated hypermetabolic areas that
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were restricted to the cranium and dura. The tumor was classifi ed as stage IE.
Postoperatively, the patient was treated with six cycles of R-CHOP combination chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) without complication. Repeat PET after four cycles detected no evidence of disease. The patient subsequently underwent frontal skull reconstructive surgery, and at the 1-year follow-up she was doing well with no evidence of disease.
Discussion
Primary lymphoma of bone is a rare clinical entity that accounts for 3% of all bone malignancies 1 and about 5% of all extranodal non-Hodgkin lymphomas. 2 A true primary malignant lymphoma of bone is defi ned as "a solitary mass lesion [in a patient] with no evidence of disease at other sites and no systemic dissemination within 6 months of the detection of tumor." 3 Onset usually occurs in the fi fth or sixth decade of life. 4, 5 Diffuse large-cell lymphoma is the most common histologic subtype of non-Hodgkin lymphoma; the B-cell immunophenotype is predominant. 6, 7 The femur is the most commonly affected site, accounting for 25% of cases; other sites include the pelvis, humerus, and tibia. 8 Primary lymphoma arising from the calvaria is extremely rare; to the best of our knowledge, only 17 such cases have been reported in the literature. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] (We do not include in this total the many case reports of skull involvement as a part of systemic lymphoma.)
The most common presentation is pain and swelling of the involved bone, which is very similar to our patient's presentation. Patients with primary lymphoma Figure 1 . Contrast-enhanced axial CT shows a lobulated, hyperdense, aggressive-appearing transcranial mass (arrow) involving the right frontal bone with extension both inside and outside the skull. Vasogenic edema is seen in the frontal lobe with some mass effect on the right frontal horn. of bone may have systemic B symptoms (fever, weight loss, and night sweats); these symptoms can be easily confused with those of infectious causes such as osteomyelitis. 18 High-grade lymphomas that involve bone are characterized by a permeative growth pattern and a large soft-tissue component in the extradural and galeal compartments; these features are occasionally accompanied by limited destruction of cortical bone, 18 as occurred in our patient. This presentation is also seen in patients with osteomyelitis, although they usually exhibit systemic signs, which our patient did not. Other diseases that can mimic primary lymphoma of the skull include extradural hematoma, meningioma, and metastatic carcinoma. The traditional Ann Arbor staging classifi cation for Hodgkin lymphoma is used to stage patients with primary lymphoma of bone. PET is very useful for evaluating the extent and stage of disease. In our patient, PET demonstrated uptake in both tonsils and the nasopharynx, away from the primary site in the frontal bone. But because the scan had been performed after a neurosurgical procedure that had required intubation, these areas of uptake in the throat might have represented false positives, refl ecting the trauma of intubation. In order to have obtained a biopsy of these areas, we would have had to administer pharmacologic sedation to our patient because of her signifi cant upper extremity chorea. Therefore, additional biopsies were deferred, and debate ensued as to how this case should be staged-as stage IE or stage IVA.
Figure 2. A: T2-weighted axial MRI shows the lobulated transcranial mass in the right frontal area (arrow) and the vasogenic edema of the brain. The hypointensity of the mass indicates dense cellularity and a high nucleus-to-cytoplasm ratio, which is not very typical of lymphoma. B: Contrast-enhanced T1-weighted image shows an intensely enhancing transcranial mass and the destruction of the frontal bone (arrow).
No consensus has emerged regarding the optimal treatment for primary lymphoma of bone. In the 1960s, radiation therapy was established as the standard of care. But while it resulted in good local control, it was associated with relatively high rates of systemic failure. [23] [24] [25] Subsequently, better survival was reported with the use of combined chemo-and radiotherapy as opposed to radiotherapy alone. 26 In addition, Beal et al studied a series of 82 patients with primary lymphoma of bone and found that combination chemotherapy was superior to radiotherapy alone. 27 Several studies have suggested that CHOP administered at 3-week intervals improves both overall survival and progression-free survival. [28] [29] [30] The addition to CHOP of rituximab-a therapeutic antibody directed against the CD20 surface antigen that is frequently present in lymphoma cells-further improves response rates and survival in patients whose lymphoma expresses the CD20 antigen. Our patient was started on R-CHOP, and she was able to successfully complete six cycles of chemotherapy without experiencing limiting toxicities. Her follow-up PET study revealed a complete response to therapy, which allowed her to undergo subsequent reconstructive surgery of the frontal bone.
In summary, primary lymphoma of the skull is rarely considered in the differential diagnosis of a mass in the calvaria in patients without constitutional manifestations such as fever, weight loss, and night sweats. It can mimic osteomyelitis, extradural hematoma, meningioma, and metastatic carcinoma. Primary lymphoma of the skull should be differentiated from other primary bone tumors because it responds better to treatment. Combination chemotherapy is currently the best treatment option available.
